What's Happening?
EVERSANA has appointed Jen Norton as the president of its Market Access & Value division. Norton will lead the development of a technology-first, fully integrated market access business unit. This move aims to help life sciences companies navigate the increasingly
complex pricing and access landscape, influenced by initiatives like Medicare price negotiations and most-favored nation policies in the U.S. Norton brings over two decades of experience, having previously held leadership roles at Takeda Pharmaceuticals, Amgen, Biogen, and Vertex Pharma. Her expertise is expected to enhance EVERSANA's commitment to global pricing, revenue management, and consulting offerings.
Why It's Important?
The appointment of Jen Norton is significant as it underscores EVERSANA's strategic focus on addressing the challenges faced by life sciences companies in securing optimal pricing and broad payer coverage. With the evolving healthcare landscape, marked by regulatory reforms and international trade impacts, Norton's leadership is poised to drive patient access to therapies. This development is crucial for pharmaceutical companies aiming to maintain competitiveness and ensure that patients receive necessary treatments amidst changing market dynamics.
